Biblio

Export 66 results:
Author Title Type [ Year(Asc)]
Filters: Keyword is Peptide Fragments  [Clear All Filters]
2016
M. Fà, Zhang, H., Staniszewski, A., Saeed, F., Shen, L. W., Schiefer, I. T., Siklos, M. I., Tapadar, S., Litosh, V. A., Libien, J., Petukhov, P. A., Teich, A. F., Thatcher, G. R. J., and Arancio, O., Novel Selective Calpain 1 Inhibitors as Potential Therapeutics in Alzheimer's Disease., J Alzheimers Dis, vol. 49, no. 3, pp. 707-21, 2016.
D. A. Nation, Ho, J., and Yew, B., Older Adults Taking AT1-Receptor Blockers Exhibit Reduced Cerebral Amyloid Retention., J Alzheimers Dis, vol. 50, no. 3, pp. 779-89, 2016.
P. Banerjee, Sahoo, A., Anand, S., Bir, A., and Chakrabarti, S., The Oral Iron Chelator, Deferasirox, Reverses the Age-Dependent Alterations in Iron and Amyloid-β Homeostasis in Rat Brain: Implications in the Therapy of Alzheimer's Disease., J Alzheimers Dis, vol. 49, no. 3, pp. 681-93, 2016.
M. Babić Leko, Borovečki, F., Dejanović, N., Hof, P. R., and Šimić, G., Predictive Value of Cerebrospinal Fluid Visinin-Like Protein-1 Levels for Alzheimer's Disease Early Detection and Differential Diagnosis in Patients with Mild Cognitive Impairment., J Alzheimers Dis, vol. 50, no. 3, pp. 765-78, 2016.
K. Bourgade, Le Page, A., Bocti, C., Witkowski, J. M., Dupuis, G., Frost, E. H., and Fülöp, T., Protective Effect of Amyloid-β Peptides Against Herpes Simplex Virus-1 Infection in a Neuronal Cell Culture Model., J Alzheimers Dis, vol. 50, no. 4, pp. 1227-41, 2016.
S. Tholen, Schmaderer, C., Chmielewski, S., Förstl, H., Heemann, U., Baumann, M., Steubl, D., and Grimmer, T., Reduction of Amyloid-β Plasma Levels by Hemodialysis: An Anti-Amyloid Treatment Strategy?, J Alzheimers Dis, vol. 50, no. 3, pp. 791-6, 2016.
J. Bennett, Burns, J., Welch, P., and Bothwell, R., Safety and Tolerability of R(+) Pramipexole in Mild-to-Moderate Alzheimer's Disease., J Alzheimers Dis, vol. 49, no. 4, pp. 1179-87, 2016.
L. García Barrado, Coart, E., Vanderstichele, H. M. J., and Burzykowski, T., Transferring cut-off values between assays for cerebrospinal fluid Alzheimer's disease biomarkers., J Alzheimers Dis, vol. 49, no. 1, pp. 187-99, 2016.
F. Pasquier, Sadowsky, C., Holstein, A., Leterme, G. Le Prince, Peng, Y., Jackson, N., Fox, N. C., Ketter, N., Liu, E., and J Ryan, M., Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease., J Alzheimers Dis, vol. 51, no. 4, pp. 1131-43, 2016.
D. Andriuta, Moullart, V., Schraen, S., Devendeville, A., Meyer, M. - E., and Godefroy, O., What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?, J Alzheimers Dis, vol. 51, no. 3, pp. 793-800, 2016.

Pages